ChromaDex (NASDAQ:CDXC) Sets New 1-Year High – What’s Next?

ChromaDex Co. (NASDAQ:CDXC)’s stock price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $7.58 and last traded at $7.50, with a volume of 586086 shares. The stock had previously closed at $7.27.

Analyst Upgrades and Downgrades

CDXC has been the subject of a number of research reports. StockNews.com downgraded ChromaDex from a “strong-buy” rating to a “buy” rating in a research report on Monday. Roth Mkm increased their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Finally, HC Wainwright boosted their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 4th.

ChromaDex Stock Performance

The company has a market capitalization of $574.38 million, a P/E ratio of 752.75 and a beta of 1.88. The firm’s fifty day moving average is $4.28 and its 200 day moving average is $3.48.

ChromaDex (NASDAQ:CDXC) last issued its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. The firm had revenue of $25.58 million for the quarter, compared to the consensus estimate of $23.70 million. During the same period in the prior year, the business posted ($0.01) earnings per share. On average, analysts forecast that ChromaDex Co. will post 0.04 EPS for the current year.

Insider Transactions at ChromaDex

In other ChromaDex news, Director Kristin Patrick sold 23,000 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $3.57, for a total value of $82,110.00. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 9.64% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. OneDigital Investment Advisors LLC boosted its stake in shares of ChromaDex by 5.5% during the third quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company’s stock valued at $217,000 after purchasing an additional 3,097 shares in the last quarter. MetLife Investment Management LLC boosted its position in ChromaDex by 39.3% during the 3rd quarter. MetLife Investment Management LLC now owns 18,114 shares of the company’s stock valued at $66,000 after acquiring an additional 5,115 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of ChromaDex by 75.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,732 shares of the company’s stock valued at $72,000 after acquiring an additional 8,485 shares during the period. Miracle Mile Advisors LLC bought a new position in shares of ChromaDex in the 2nd quarter worth $27,000. Finally, The Manufacturers Life Insurance Company bought a new position in ChromaDex in the second quarter worth about $31,000. Institutional investors own 15.41% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.